AP2436A - Immunogenic composition - Google Patents

Immunogenic composition

Info

Publication number
AP2436A
AP2436A AP2007004274A AP2007004274A AP2436A AP 2436 A AP2436 A AP 2436A AP 2007004274 A AP2007004274 A AP 2007004274A AP 2007004274 A AP2007004274 A AP 2007004274A AP 2436 A AP2436 A AP 2436A
Authority
AP
ARIPO
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Application number
AP2007004274A
Other languages
English (en)
Other versions
AP2007004274A0 (en
Inventor
Ralph Leon Biemans
Dominique Boutriau
Carine Capiau
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36716943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0513069.5A external-priority patent/GB0513069D0/en
Priority claimed from GBGB0513071.1A external-priority patent/GB0513071D0/en
Priority claimed from GB0515556A external-priority patent/GB0515556D0/en
Priority claimed from GB0524204A external-priority patent/GB0524204D0/en
Priority claimed from GB0526041A external-priority patent/GB0526041D0/en
Priority claimed from GB0526040A external-priority patent/GB0526040D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AP2007004274A0 publication Critical patent/AP2007004274A0/xx
Application granted granted Critical
Publication of AP2436A publication Critical patent/AP2436A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Surgical Instruments (AREA)
AP2007004274A 2005-06-27 2006-06-23 Immunogenic composition AP2436A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0513069.5A GB0513069D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GBGB0513071.1A GB0513071D0 (en) 2005-06-27 2005-06-27 Immunogenic composition
GB0515556A GB0515556D0 (en) 2005-07-28 2005-07-28 Immunogenic composition
GB0524204A GB0524204D0 (en) 2005-11-28 2005-11-28 Immunogenic composition
GB0526041A GB0526041D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526040A GB0526040D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
PCT/EP2006/006220 WO2007000327A1 (en) 2005-06-27 2006-06-23 Immunogenic composition

Publications (2)

Publication Number Publication Date
AP2007004274A0 AP2007004274A0 (en) 2007-12-31
AP2436A true AP2436A (en) 2012-08-31

Family

ID=36716943

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004274A AP2436A (en) 2005-06-27 2006-06-23 Immunogenic composition

Country Status (36)

Country Link
US (13) US8329184B2 (de)
EP (11) EP2201961B1 (de)
JP (9) JP5280199B2 (de)
KR (7) KR101351870B1 (de)
CN (3) CN103083657B (de)
AP (1) AP2436A (de)
AR (3) AR056396A1 (de)
AT (3) ATE462444T1 (de)
AU (7) AU2006263944B2 (de)
BE (1) BE2012C042I2 (de)
BR (5) BRPI0612656B1 (de)
CA (5) CA2611960C (de)
CY (5) CY1109996T1 (de)
DE (1) DE602006013313D1 (de)
DK (7) DK1896063T3 (de)
EA (4) EA012506B1 (de)
ES (9) ES2621780T3 (de)
FR (1) FR22C1008I2 (de)
HR (4) HRP20120102T1 (de)
HU (7) HUE056842T2 (de)
IL (8) IL187924A (de)
LT (2) LT2351578T (de)
LU (2) LU92085I2 (de)
MA (4) MA29603B1 (de)
MX (5) MX2007016402A (de)
MY (3) MY148110A (de)
NL (2) NL300549I2 (de)
NO (4) NO345422B1 (de)
NZ (6) NZ564371A (de)
PE (6) PE20110096A1 (de)
PL (8) PL1896065T5 (de)
PT (8) PT3009146T (de)
SI (8) SI1896063T1 (de)
TW (5) TW201336507A (de)
UA (2) UA95238C2 (de)
WO (6) WO2007000314A2 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AR056396A1 (es) 2005-06-27 2007-10-10 Glaxosmithkline Biolog Sa Composicion inmunogenica
BRPI0615420A2 (pt) * 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
AU2012261764B2 (en) * 2005-09-01 2016-09-08 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup C meningococcus
TR201900418T4 (tr) 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ATE554788T1 (de) * 2006-03-22 2012-05-15 Novartis Ag Schemata zur immunisierung mit meningokokken- konjugaten
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EA020817B1 (ru) * 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX340096B (es) 2007-10-19 2016-06-27 Glaxosmithkline Biologicals Sa Formulaciones de vacuna meningococica.
KR20110050531A (ko) * 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
HUE029265T2 (en) 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
JP5593626B2 (ja) * 2009-03-31 2014-09-24 凸版印刷株式会社 計量スプーン
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
CA2757620C (en) * 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
RU2536981C9 (ru) 2009-06-22 2015-05-10 ВАЙЕТ ЭлЭлСи Иммуногенные композиции антигенов staphylococcus aureus
NZ597191A (en) * 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
JP5988492B2 (ja) 2009-09-02 2016-09-07 ノバルティス アーゲー Ｔｌｒ活性モジュレーターを含む免疫原性組成物
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011051917A1 (en) 2009-10-30 2011-05-05 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
EP3246044B2 (de) 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
EP2480253B1 (de) 2010-09-01 2014-01-22 Novartis AG Adsorption von immunpotentiatoren auf unlöslichen metallsalzen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2013112653A (ja) * 2011-11-30 2013-06-10 Jnc Corp 新規重合体およびその製造方法
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
BR112014018815B1 (pt) * 2012-01-30 2022-07-12 Serum Institute Of India Ltd. Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
CN102569723A (zh) * 2012-02-13 2012-07-11 华为技术有限公司 锂离子电池正极材料及其制备方法、正极及锂离子电池
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
EP2822584A1 (de) 2012-03-08 2015-01-14 Novartis AG Kombinationsimpfstoffe mit tlr4-agonisten
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) * 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
ITMI20121597A1 (it) * 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
BR112015007126A2 (pt) 2012-10-02 2017-08-08 Glaxosmithkline Biologicals Sa composição, método para induzir uma resposta imune, e, uso de uma composição
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2014147044A1 (en) * 2013-03-18 2014-09-25 Glaxosmithkline Biologicals S.A. Method of treatment
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
IN2014DE02450A (de) 2013-09-25 2015-06-26 Suzuki Motor Corp
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
IL296681B2 (en) * 2014-01-21 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP2921856B1 (de) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited Quantitativer test für 4-pyrrolidinopyridin (4-ppy) in konjugatimpfstoffen aus polysaccharid-protein
EP3131576B1 (de) * 2014-04-17 2021-06-30 Medizinische Hochschule Hannover Mittel und verfahren zur herstellung von neisseria meningitidis kapsel-polysacchariden mit geringer dispersität
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
TWI756893B (zh) * 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
US20170333546A1 (en) * 2015-12-08 2017-11-23 Jl Medical Corporation Method for Producing and Vaccine Composition of Neisseria Meningitidis Serogroups A, C, Y, and W-135 Oligosaccharides Conjugated to Glycan-Free Carrier Protein
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
CN118236477B (zh) * 2016-09-02 2025-04-25 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
WO2018053004A2 (en) 2016-09-13 2018-03-22 Allergan, Inc. Non-protein clostridial toxin compositions
CN109922828A (zh) * 2016-10-20 2019-06-21 Km生物医药股份公司 使用具有降低了的分子量的PRP的Hib结合疫苗的制造方法
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US20200353064A1 (en) * 2018-01-29 2020-11-12 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel meningococcal vaccine composition and process thereof
WO2019198096A1 (en) * 2018-04-11 2019-10-17 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Tetravalent meningococcal vaccine composition and process to prepare thereof
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112023009109A2 (pt) 2020-11-13 2024-02-06 Glaxosmithkline Biologicals Sa Carreadores de proteína bacteriana e métodos de conjugação
RU2770877C1 (ru) * 2021-04-08 2022-04-22 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ получения антигенной конъюгированной субстанции гемофильного типа b микроба для создания вакцинных препаратов
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN121569027A (zh) 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
WO2002080965A2 (en) * 2001-04-03 2002-10-17 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2005032583A2 (en) * 2003-10-02 2005-04-14 Chiron Srl Liquid vaccines for multiple meningococcal serogroups

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB513069A (en) 1937-04-24 1939-10-03 Linde Air Prod Co Improvements in method of and apparatus for the treatment of metallic bodies by oxidising gas
GB505518A (en) 1938-02-03 1939-05-12 Daniel Morgan Skeins Improvements in or relating to envelopes
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4123520A (en) * 1977-08-01 1978-10-31 Merck & Co., Inc. Method for preparing high molecular weight meningococcal Group C vaccine
DE2748132A1 (de) * 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4235994A (en) * 1978-06-26 1980-11-25 Merck & Co., Inc. High molecular weight meningococcal group C vaccine and method for preparation thereof
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
EP0027888B1 (de) 1979-09-21 1986-04-16 Hitachi, Ltd. Halbleiterschalter
DE3040825A1 (de) * 1980-10-30 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach Neues tridekapeptid, verfahren zu seiner herstellung und verwendung
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NL8500370A (nl) * 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DE3526940A1 (de) 1985-07-27 1987-02-12 Siegfried Fricker Anker zum einbetonieren in schwere lasten
IL78929A0 (en) 1985-07-29 1986-09-30 Abbott Lab Microemulsion compositions for parenteral administration
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5180815A (en) * 1988-04-13 1993-01-19 Fuji Photo Film Co., Ltd. Modified protein for carrying hapten
JPH03504564A (ja) 1988-05-31 1991-10-09 ベアトリーセ　ケーニッヒ‐ハウク 棚装置
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
EP0482068A1 (de) 1989-07-14 1992-04-29 American Cyanamid Company Cytokin- und hormonträger zur verwendung bei konjugatimpfstoffen
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
RU2105568C1 (ru) 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB2264352A (en) 1992-01-31 1993-08-25 Richards Eng Ltd Incineration apparatus
AU685047B2 (en) 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
EP0642355B1 (de) 1992-05-23 1998-07-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
SG47725A1 (en) 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
DE69317556T2 (de) 1992-12-14 1998-07-09 I/O Exploration Products (Usa), Inc., Stafford, Tex. Hydraulischer seismischer aktuator
KR100376361B1 (ko) 1993-09-22 2003-07-18 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
US5869058A (en) 1994-05-25 1999-02-09 Yeda Research And Development Co. Ltd. Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
CA2215933C (en) 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
DK1090642T3 (da) 1995-06-07 2008-09-22 Glaxosmithkline Biolog Sa Vacciner omfattende et polysaccharidantigen-bæreprotein-konjugat og frit bæreprotein
IL122588A (en) 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69712219T2 (de) 1996-10-23 2002-12-12 Matsushita Electric Industrial Co., Ltd. Optische platte
JP2001501833A (ja) 1996-10-31 2001-02-13 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅのポリヌクレオチドおよび配列
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ATE316797T1 (de) 1997-09-15 2006-02-15 Sanofi Pasteur Msd Verfahren zur herstellung multivalenter impfstoffe
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
HK1041825B (zh) 1998-08-19 2007-02-23 Baxter Healthcare S.A. 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
WO2000033882A1 (en) † 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1156781B1 (de) 1999-02-26 2005-06-08 Chiron Corporation Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
BR0009166A (pt) * 1999-03-19 2001-12-26 Smithkline Beecham Biolog Vacina
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP4660043B2 (ja) * 1999-06-25 2011-03-30 ワイス・ホールディングズ・コーポレイション グラム陰性細菌のペプチドグリカン結合リポタンパク質の脂質化された形態の製造
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
EP2292263A3 (de) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und methoden zur stabilisierung von biologischen Molekülen nach Lyophilisierung
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002009643A2 (en) * 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
MXPA03003690A (es) * 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
NZ622900A (en) 2001-01-23 2015-11-27 Sanofi Pasteur Inc Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US6615062B2 (en) 2001-05-31 2003-09-02 Infraredx, Inc. Referencing optical catheters
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CU23031A1 (es) 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
US7615229B2 (en) 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
DK1777236T3 (en) 2002-03-26 2017-02-27 Glaxosmithkline Biologicals Sa MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
CN1816350B (zh) 2002-05-14 2010-11-10 莱顿大学 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
ES2537737T3 (es) 2002-08-02 2015-06-11 Glaxosmithkline Biologicals S.A. Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB
GB0220199D0 (en) 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
CN1401328A (zh) 2002-10-18 2003-03-12 北京绿竹生物技术有限责任公司 流行性脑脊髓膜炎多糖－蛋白结合疫苗
MXPA05004528A (es) * 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CN1168501C (zh) 2002-12-27 2004-09-29 北京绿竹生物技术有限责任公司 一种多糖-蛋白结合疫苗
CN101926988B (zh) * 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2812817C (en) 2003-03-13 2016-12-20 Glaxosmithkline Biologicals S.A. Method of detoxification of pneumolysin
EP1603950A2 (de) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutiertes choleraholotoxin als adjuvans und antigenträgerprotein
WO2004103400A2 (en) 2003-05-07 2004-12-02 Aventis Pasteur,Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
DE602004022286D1 (de) 2003-06-02 2009-09-10 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
MXPA05014171A (es) 2003-06-23 2007-02-21 Sanofi Pasteur Inc Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c.
KR101034055B1 (ko) 2003-07-18 2011-05-12 엘지이노텍 주식회사 발광 다이오드 및 그 제조방법
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CN103623405B (zh) * 2003-08-06 2016-06-15 美国政府健康及人类服务部 多糖-蛋白轭合物疫苗
JP2007502980A (ja) * 2003-08-21 2007-02-15 アプレラ コーポレイション Ｍａｌｄｉ質量分析法のためのマトリックス干渉の軽減
CA2539715C (en) * 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
EP1706481A2 (de) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Impfstoff
GB0405787D0 (en) † 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
EP1742659B1 (de) * 2004-04-05 2013-03-13 Pah Usa 15 Llc Mikrofluidisierte öl-in-wasser-emulsionen und vakzinezusammensetzungen
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0413868D0 (en) * 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
BR122016029840B1 (pt) * 2004-09-22 2021-10-13 Glaxosmithkline Biologicals S.A. Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0505518D0 (en) † 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) * 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
PT1885734E (pt) 2005-05-06 2015-03-04 Novartis Ag Imunogénios para vacinas contra a meningite-a
AR056396A1 (es) * 2005-06-27 2007-10-10 Glaxosmithkline Biolog Sa Composicion inmunogenica
CN1709505B (zh) 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 多价细菌荚膜多糖-蛋白质结合物联合疫苗
BRPI0615420A2 (pt) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic vacinação múltipla que inclui meningococo do sorogrupo c
US8679770B2 (en) 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
TR201900418T4 (tr) * 2005-12-22 2019-02-21 Glaxosmithkline Biologicals Sa Pnömokok polisakkarit konjugat aşısı.
EP1940462A2 (de) * 2005-12-23 2008-07-09 GlaxoSmithKline Biologicals S.A. Konjugatimpfstoffe
KR101711903B1 (ko) * 2006-03-17 2017-03-03 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
WO2008001224A2 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
BRPI0714714A2 (pt) 2006-07-21 2013-04-09 Univ California composiÇÕes de polipeptÍdeo de retrovÍrus endàgeno humano e (herv) e seus mÉtodos e usos
CA2662051A1 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
JP4858611B2 (ja) 2007-03-14 2012-01-18 コニカミノルタビジネステクノロジーズ株式会社 情報埋め込み方法、そのプログラムおよび情報埋め込み装置
PE20090212A1 (es) * 2007-05-02 2009-03-30 Glaxosmithkline Biolog Sa Kit de vacuna para la inmunizacion primaria
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR20110050531A (ko) * 2008-08-28 2011-05-13 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
US8259461B2 (en) * 2008-11-25 2012-09-04 Micron Technology, Inc. Apparatus for bypassing faulty connections
US8974799B2 (en) * 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2545068B8 (de) * 2010-03-11 2018-03-21 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung oder impfstoff gegen infektion oder krankheit mit gram-negativen bakterien wie z.b. neisseria
JP5144836B2 (ja) 2010-06-11 2013-02-13 パナソニック株式会社 語音聴取の評価システム、その方法およびそのプログラム
JP6170932B2 (ja) * 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
BR112014018815B1 (pt) * 2012-01-30 2022-07-12 Serum Institute Of India Ltd. Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
WO2014001328A1 (en) 2012-06-25 2014-01-03 Nadiro A/S A lifeboat deployment unit
PT2928489T (pt) * 2012-12-05 2019-05-28 Glaxosmithkline Biologicals Sa Composição imunogénica
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015299008B2 (en) * 2014-08-05 2018-08-02 Glaxosmithkline Biologicals S.A. Carrier molecule for antigens
TWI715617B (zh) * 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518684D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CN118236477B (zh) * 2016-09-02 2025-04-25 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) * 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
PE20191107A1 (es) * 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
EA202090316A1 (ru) * 2017-07-18 2020-12-08 Серум Инститьют Оф Индия Пвт Лтд. Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000249A2 (en) * 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
WO2002080965A2 (en) * 2001-04-03 2002-10-17 Glaxosmithkline Biologicals S.A. Vaccine composition
WO2005032583A2 (en) * 2003-10-02 2005-04-14 Chiron Srl Liquid vaccines for multiple meningococcal serogroups

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EDA TAMM ET AL.: "Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate" VACCINE, vol. 23, February 2005 (2005-02), pages 1715-1719, XP004739805 � *

Also Published As

Publication number Publication date
MX2007016402A (es) 2008-03-07
US20080199490A1 (en) 2008-08-21
TWI477283B (zh) 2015-03-21
BRPI0612669A2 (pt) 2010-11-30
US20130004532A1 (en) 2013-01-03
CN102218138A (zh) 2011-10-19
ES2747025T3 (es) 2020-03-09
JP2015134829A (ja) 2015-07-27
EP2283857B1 (de) 2019-07-24
US20090252759A1 (en) 2009-10-08
SI2283857T1 (sl) 2019-11-29
BRPI0612655A2 (pt) 2010-11-30
SI1896061T1 (sl) 2019-10-30
PL1896062T3 (pl) 2010-08-31
LT2351578T (lt) 2017-04-10
DK1896065T3 (da) 2011-08-29
NZ564370A (en) 2011-10-28
CY2012027I2 (el) 2015-10-07
ES2898451T3 (es) 2022-03-07
CN103083657A (zh) 2013-05-08
PT1896062E (pt) 2010-05-17
AU2006263944A1 (en) 2007-01-04
LTPA2012019I1 (lt) 2012-11-26
UA95237C2 (uk) 2011-07-25
US9789179B2 (en) 2017-10-17
NL301151I2 (nl) 2025-12-15
DK1896061T3 (da) 2019-08-26
WO2007000343A2 (en) 2007-01-04
BRPI0612669B1 (pt) 2019-08-13
SI1896065T2 (sl) 2014-12-31
NZ564371A (en) 2010-05-28
DE602006013313D1 (de) 2010-05-12
EP1896063A1 (de) 2008-03-12
WO2007000341A2 (en) 2007-01-04
NZ564607A (en) 2011-06-30
EA200702576A1 (ru) 2008-06-30
PT3009146T (pt) 2021-11-30
BRPI0612656B1 (pt) 2021-09-08
IL188045A0 (en) 2008-03-20
TW200738259A (en) 2007-10-16
WO2007000314A3 (en) 2007-05-31
EA012214B1 (ru) 2009-08-28
EP1896064A2 (de) 2008-03-12
BRPI0612669B8 (pt) 2021-05-25
EA200702575A1 (ru) 2008-06-30
US20180064806A1 (en) 2018-03-08
KR101532068B1 (ko) 2015-06-29
HUE045482T2 (hu) 2019-12-30
US20190298822A1 (en) 2019-10-03
CA2611964A1 (en) 2007-01-04
KR20080018216A (ko) 2008-02-27
PT2351578T (pt) 2017-04-07
EP1896065B2 (de) 2014-09-03
EP1896061B1 (de) 2019-06-12
PL1896065T3 (pl) 2011-12-30
WO2007000342A3 (en) 2007-05-31
CN102526723B (zh) 2017-07-07
MA29993B1 (fr) 2008-12-01
AU2006263963B2 (en) 2010-05-13
BRPI0612654A2 (pt) 2012-10-02
KR101351870B1 (ko) 2014-02-17
HK1116414A1 (en) 2008-12-24
CA2611960C (en) 2015-05-05
KR20080025184A (ko) 2008-03-19
JP5718960B2 (ja) 2015-05-13
WO2007000341A3 (en) 2007-05-31
HRP20110567T1 (en) 2011-09-30
LUC00247I2 (de) 2024-10-04
IL187924A (en) 2011-11-30
IL213795A0 (en) 2011-07-31
US20090136541A1 (en) 2009-05-28
JP5297800B2 (ja) 2013-09-25
PL1896065T5 (pl) 2014-12-31
HK1116413A1 (en) 2008-12-24
TW200730187A (en) 2007-08-16
DK1896063T3 (da) 2012-03-19
PE20070123A1 (es) 2007-02-08
ES2741529T3 (es) 2020-02-11
EP1896062A1 (de) 2008-03-12
NZ564605A (en) 2011-01-28
JP2008543909A (ja) 2008-12-04
AU2006263944B2 (en) 2012-03-01
PT1896063E (pt) 2012-02-13
US10166287B2 (en) 2019-01-01
ES2377075T5 (es) 2016-04-29
LU92085I9 (de) 2019-01-04
EP3009146B1 (de) 2021-10-20
BRPI0612654B1 (pt) 2021-05-04
IL213718A0 (en) 2011-07-31
CA2612957C (en) 2016-07-19
JP2013018798A (ja) 2013-01-31
CA2612980A1 (en) 2007-01-04
DK2283857T3 (da) 2019-10-28
AR056396A1 (es) 2007-10-10
MY147490A (en) 2012-12-14
CN103083657B (zh) 2016-06-08
AU2006263936A1 (en) 2007-01-04
ES2377075T3 (es) 2012-03-22
NO345422B1 (no) 2021-01-25
MX2007016236A (es) 2008-03-07
HK1114011A1 (en) 2008-10-24
BRPI0612654B8 (pt) 2021-05-25
IL188072A (en) 2017-07-31
DK2351578T3 (en) 2017-04-24
US20090041802A1 (en) 2009-02-12
JP2008543905A (ja) 2008-12-04
US8329184B2 (en) 2012-12-11
CY2012027I1 (el) 2015-10-07
EP1896062B1 (de) 2010-03-31
NO20076343L (no) 2008-03-25
AR053935A1 (es) 2007-05-23
CA2612957A1 (en) 2007-01-04
CA2611960A1 (en) 2007-01-04
HUE047211T2 (hu) 2020-04-28
EP2351578B1 (de) 2017-01-18
US9486515B2 (en) 2016-11-08
BRPI0612670B8 (pt) 2021-05-25
US20100215686A1 (en) 2010-08-26
HRP20110567T4 (xx) 2015-01-16
KR101408113B1 (ko) 2014-06-16
BRPI0612670B1 (pt) 2020-04-28
UA95238C2 (uk) 2011-07-25
PT1896061T (pt) 2019-08-01
HK1206587A1 (en) 2016-01-15
ATE536884T1 (de) 2011-12-15
IL187924A0 (en) 2008-03-20
NO20076350L (no) 2008-03-26
ES2750243T3 (es) 2020-03-25
SI1896062T1 (sl) 2010-07-30
WO2007000342A2 (en) 2007-01-04
HUS1200023I1 (hu) 2021-03-29
DK1896065T4 (da) 2014-10-20
EP2878307B1 (de) 2019-07-24
BRPI0612656A8 (pt) 2018-01-23
US8431136B2 (en) 2013-04-30
PL2283857T3 (pl) 2020-02-28
MX2007016237A (es) 2008-03-07
AU2010203115C1 (en) 2013-05-02
US20200000911A1 (en) 2020-01-02
AU2006263963A1 (en) 2007-01-04
MY148110A (en) 2013-02-28
WO2007000322A1 (en) 2007-01-04
EP1896065B1 (de) 2011-07-20
CA2611964C (en) 2016-11-08
IL222346A (en) 2015-07-30
SI1896065T1 (sl) 2011-10-28
JP2013209395A (ja) 2013-10-10
EP2351578A1 (de) 2011-08-03
JP5965512B2 (ja) 2016-08-03
TW201336507A (zh) 2013-09-16
EP2878307A1 (de) 2015-06-03
AU2006263964B2 (en) 2010-05-20
TW201414490A (zh) 2014-04-16
EA200702577A1 (ru) 2008-06-30
HRP20170457T1 (hr) 2017-05-19
ES2340711T3 (es) 2010-06-08
TWI407970B (zh) 2013-09-11
EP1896063B2 (de) 2016-03-02
WO2007000343A3 (en) 2007-05-31
MA29602B1 (fr) 2008-07-01
ES2901378T3 (es) 2022-03-22
MA29603B1 (fr) 2008-07-01
EP1896066A2 (de) 2008-03-12
JP5769688B2 (ja) 2015-08-26
EA012528B1 (ru) 2009-10-30
BRPI0612655A8 (pt) 2018-01-30
HUE046905T2 (hu) 2020-03-30
IL188072A0 (en) 2008-03-20
AU2010203115A1 (en) 2010-08-12
PT1896065E (pt) 2011-08-31
NZ564606A (en) 2010-10-29
WO2007000327A1 (en) 2007-01-04
LTC1896065I2 (lt) 2025-06-10
HRP20100211T1 (hr) 2010-05-31
KR20130122810A (ko) 2013-11-08
PT2878307T (pt) 2019-10-24
JP5731737B2 (ja) 2015-06-10
JP2008543908A (ja) 2008-12-04
EP1896066B8 (de) 2022-01-19
FR22C1008I1 (fr) 2022-04-29
NO20076363L (no) 2008-03-26
EA012506B1 (ru) 2009-10-30
AR056397A1 (es) 2007-10-10
NO20076302L (no) 2008-03-26
PL2878307T3 (pl) 2020-01-31
SI3009146T1 (sl) 2022-02-28
EP2201961B1 (de) 2018-01-24
FR22C1008I2 (fr) 2024-01-19
EP1896063B1 (de) 2011-12-14
MX2007016405A (es) 2008-03-07
PE20070499A1 (es) 2007-05-21
EA013374B1 (ru) 2010-04-30
EP3009146A1 (de) 2016-04-20
NL300549I2 (de) 2017-01-03
NO345305B1 (no) 2020-12-07
PE20110072A1 (es) 2011-02-04
US11241495B2 (en) 2022-02-08
AP2007004274A0 (en) 2007-12-31
EP1896065A2 (de) 2008-03-12
US9358279B2 (en) 2016-06-07
CY1111827T1 (el) 2015-10-07
EP1896061A2 (de) 2008-03-12
PL1896061T3 (pl) 2020-02-28
CN102526723A (zh) 2012-07-04
IL213718A (en) 2013-07-31
PL3009146T3 (pl) 2022-02-07
AU2010212417A1 (en) 2010-09-09
NZ590204A (en) 2012-02-24
WO2007000314A2 (en) 2007-01-04
AU2006263936B2 (en) 2010-05-20
KR20080024222A (ko) 2008-03-17
HUE056842T2 (hu) 2022-03-28
BRPI0612656A2 (pt) 2010-11-30
US8846049B2 (en) 2014-09-30
EP2201961A1 (de) 2010-06-30
BE2012C042I2 (de) 2021-07-19
EP2283857A1 (de) 2011-02-16
ES2662651T3 (es) 2018-04-09
HUS000497I2 (hu) 2021-03-29
AU2010203115B2 (en) 2012-03-15
NO342815B1 (no) 2018-08-13
JP5037503B2 (ja) 2012-09-26
PE20110096A1 (es) 2011-03-07
US20130171188A1 (en) 2013-07-04
ATE462444T1 (de) 2010-04-15
PL2351578T3 (pl) 2017-07-31
ATE516816T1 (de) 2011-08-15
IL188046A0 (en) 2008-03-20
MA29569B1 (fr) 2008-06-02
SI2351578T1 (sl) 2017-05-31
KR20080018226A (ko) 2008-02-27
EP1896066B1 (de) 2021-10-27
PE20070163A1 (es) 2007-03-01
DK2878307T3 (da) 2019-10-07
KR101351873B1 (ko) 2014-02-17
WO2007000342A8 (en) 2008-07-10
IL214657A0 (en) 2011-09-27
JP2008543907A (ja) 2008-12-04
BRPI0612670A2 (pt) 2010-11-30
KR20130086087A (ko) 2013-07-30
PL1896063T3 (pl) 2012-04-30
HRP20120102T1 (hr) 2012-02-29
CY1112698T1 (el) 2016-02-10
MY147783A (en) 2013-01-31
MX2007016403A (es) 2008-03-07
CA2612963A1 (en) 2007-01-04
AU2006263965A1 (en) 2007-01-04
US20150044253A1 (en) 2015-02-12
TWI537001B (zh) 2016-06-11
DK1896062T3 (da) 2010-06-28
CA2612963C (en) 2016-10-18
LU92085I2 (fr) 2012-12-19
SI2878307T1 (sl) 2019-11-29
PT2283857T (pt) 2019-10-24
US8883163B2 (en) 2014-11-11
CY1118646T1 (el) 2017-07-12
JP5280199B2 (ja) 2013-09-04
SI1896063T1 (sl) 2012-03-30
CY1109996T1 (el) 2014-09-10
HUS2200002I1 (hu) 2022-12-28
US9931397B2 (en) 2018-04-03
KR20080030577A (ko) 2008-04-04
AU2006263965B2 (en) 2012-09-13
BRPI0612655B1 (pt) 2021-06-15
EA200702574A1 (ru) 2008-06-30
IL213795A (en) 2013-05-30
US20080193476A1 (en) 2008-08-14
CA2612980C (en) 2019-01-15
KR101359953B1 (ko) 2014-02-21
ES2621780T3 (es) 2017-07-05
PE20142165A1 (es) 2015-01-09
US20170065714A1 (en) 2017-03-09
HUE031380T2 (en) 2017-07-28
NO344452B1 (no) 2019-12-09
JP2008543904A (ja) 2008-12-04
JP2013107913A (ja) 2013-06-06
IL188046A (en) 2012-03-29
KR101321056B1 (ko) 2013-10-30
US8398983B2 (en) 2013-03-19
AU2006263964A1 (en) 2007-01-04
TWI422386B (zh) 2014-01-11
US10245317B2 (en) 2019-04-02

Similar Documents

Publication Publication Date Title
AP2436A (en) Immunogenic composition
IL182639A0 (en) Immunogenic composition
IL227934A0 (en) Immunogenic preparation
ZA200709518B (en) Vaccine composition
GB0522658D0 (en) Composition
GB0526038D0 (en) Immunogenic composition
ZA200710909B (en) Immunogenic composition
ZA200707917B (en) Composition
EP1947129A4 (de) Photoradikal- und photokationenhärtbare zusammensetzung
GB0421079D0 (en) Immunogenic composition
GB0606416D0 (en) Immunogenic composition
ZA200710854B (en) Immunogenic composition
GB0503143D0 (en) Immunogenic composition
GB0526041D0 (en) Immunogenic composition
GB0515556D0 (en) Immunogenic composition
GB0524204D0 (en) Immunogenic composition
GB0526040D0 (en) Immunogenic composition
GB0502569D0 (en) Vaccine composition
GB0421082D0 (en) Immunogenic composition
GB0421081D0 (en) Immunogenic composition
GB0421078D0 (en) Immunogenic composition
GB0606417D0 (en) Immunogenic composition
ZA200702752B (en) Immunogenic compositions
HK1116408A (en) Immunogenic composition
HK1116412A (en) Immunogenic composition